Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06067490
Other study ID # NJRJK-RC1416-Ia
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 3, 2023
Est. completion date August 18, 2024

Study information

Verified date September 2023
Source Nanjing RegeneCore Biotech Co., Ltd.
Contact Guo Qian
Phone +86-025-58608860
Email guoqian@regenecore.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.


Description:

RC1416 is a bispecific homodimer nanobody .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 48 healthy adult subjects will be enrolled in six groups to access the safety and tolerability of single subcutaneous injection of RC1416 in healthy adult subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date August 18, 2024
Est. primary completion date May 20, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Male or female aged 18 to 50 years(including the boundary value),Chinese. - Male Weight of 50 kg to 90 kg,femal weight of 40kg to 90kg, and BMI of 19.0 to 28.0 kg/m2 (including the boundary value). - Subject have no fertility, sperm/egg donation plan for at least 6 months from the signing of the informed consent to the end of the treatment, and voluntarily takes medically recognized effective non-drug contraceptive measures (including his partner) during the trial. Exclusion Criteria: - Have participated in clinical trials of drugs in other trials within 3 months prior to screening . - With clinically significant investigator-identified abnormalities of the cardiovascular, respiratory, digestive, endocrine systems (e.g., diabetes), nervous/mental systems, blood, and lymphatic systems (immune deficiency), and musculoskeletal systems. - With clinically significant infectious disease (e.g., cellulitis, abscess, or systemic infection (e.g., sepsis), or history of clinically significant opportunistic infection (e.g.,invasive candidiasis or pneumocystis pneumonia) within 3 months before to screening. - With a history of active tuberculosis or the presence of latent tuberculosis infection or active tuberculosis indicated by any current symptoms, signs or laboratory tests. - Have an allergic constitution, history of allergy to the test drug ingredient or to any drug or food or pollen. - Received chemotherapy, radiotherapy, immunosuppressive therapy, or high-dose corticosteroid treatment within 5 years before signing the informed consent. - Use of any prescription, OTC, traditional Chinese medicine, vitamin or health product within 1 month prior to screening; - Received live or attenuated vaccines within 1 month or have any vaccination schedule during the clinical trial. - Had surgery within 6 months prior to screening or planned surgery during the trial. - Have difficulty with venous blood collection, or subjects who faint at the sight of blood or a needle, or have difficulty with subcutaneous administration. - Have lost or donated blood for more than 400 mL(not including menstrual blood loss )or received blood transfusion or using blood products within 3 months before signing informed consent or planning to donate blood during the study or within 1 month after the trial. - Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 250 mL per cup) within 6 months prior to screening. - Have consumed any beverage or food containing grapefruit or caffeine (such as grapefruit juice, coffee, strong tea, chocolate, caffeinated carbonated beverages, cola, cocoa, etc.) in the 48 hours prior to screening. - Have special dietary requirements and cannot comply with a unified diet. - Smoked =5 cigarettes per day within 3 months prior to screening or or could not guarantee to quit smoking during the trial. - Regularly drank alcohol within 6 months prior to screening(i.e., more than 14 standard units per week for women and more than 21 standard units per week for men (1 standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) or could not abstinence during the trial; Or a positive alcohol breath test; - With previous history of drug abuse/drug use; Or test positive for drug abuse screening (including THC, morphine, ketamine, methamphetamine, benzodiazepines, cocaine); - Pregnant or lactating women, or positive blood pregnancy test results; - Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), human immunodeficiency virus (HIV) antigen-antibody combined detection, syphilis treponema specific antibody at the screening visit. - Subjects with the results of physical examination, vital signs, laboratory examination and other auxiliary examinations (chest imaging, abdominal B-ultrasonography, 12-lead electrocardiogram, etc.) were judged by the investigator as abnormal and clinically significant during the screening period. - The investigators considered that subjects were not suitable for this clinical trial for other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RC1416(SAD)
RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
Placebo(SAD)
Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.

Locations

Country Name City State
China China-japan Friendship Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Nanjing RegeneCore Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0 up to 92 days
Primary Vital Signs number of praticipants with clinically notable Vital Signs according to CTCAE V5.0 up to 92 days
Primary Laboratory Tests number of praticipants with clinically notable Laboratory Tests according to CTCAE V5.0 up to 92 days
Primary ECG number of praticipants with clinically notable Electrocardiogram(ECG) Values according to CTCAE V5.0 up to 92 days
Primary Injection Site Reaction number of praticipants with clinically notable Injection Site Reaction according to CTCAE V5.0 up to 4 days
Secondary Pharmacokinetics-Cmax maximum serum concentration up to 92 days
Secondary Pharmacokinetics-AUC 0-t area under the concentration-time curve (AUC) from administration to the last measurable concentration up to 92 days
Secondary Pharmacokinetics-AUC 0-inf AUC extrapolated to infinitymeasurable concentration up to 92 days
Secondary Anti-Drug antibody (ADA) number and percentage of subjects tested ADA positive up to 92 days
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1